Gilda da Cunha Santos, Neesha Dhani, Dongsheng Tu, Kayu Chin, Olga Ludkovski, Suzanne Kamel-Reid, Jeremy Squire, Wendy Parulekar, Malcolm J. Moore and Ming Sound Tsao Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer Cancer 116
Version of Record online: 7 SEP 2010 | DOI: 10.1002/cncr.25393
The role of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status and the effect of epidermal growth factor receptor (EGFR) gene copy number (GCN) were evaluated as predictive markers using mutation analysis and fluorescence in situ hybridization in a subset of patients with pancreatic cancer who had tissue samples available for analysis from the National Cancer Institute of Canada Clinical Trials Group PA.3 trial. The results indicated that EGFR GCN and KRAS mutation status do not have potential as markers for predicting a survival benefit from combined erlotinib plus gemcitabine as first-line treatment for advanced pancreatic carcinoma.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field